MedTrace Logo

HEALEY ALS Platform Trial - Regimen B Verdiperstat

NCT04436510 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 167

Last updated 2023-06-12

Study results available
· View outcomes & findings →

Summary

The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS.

Regimen B will evaluate the safety and efficacy of a single study drug, verdiperstat, in participants with ALS.

Conditions

Interventions

DRUG

Matching Placebo

Drug: Matching Placebo Administration: Oral Dose: two tablets twice daily

DRUG

Verdiperstat

Drug: Verdiperstat Administration: Oral Dose: 600mg twice daily

Sponsors & Collaborators

  • Biohaven Pharmaceuticals, Inc.

    collaborator INDUSTRY

  • Merit E. Cudkowicz, MD

    lead OTHER

Principal Investigators

  • Merit Cudkowicz, MD · Massachusetts General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-28
Primary Completion
2022-04-13
Completion
2022-12-06
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04436510 on ClinicalTrials.gov